Rev Esp Quimioter 2022;35(Suppl.1):25-27

Ceftobiprole medocaril

RAÚL MÉNDEZ, ANA LATORRE, PAULA GONZÁLEZ-JIMÉNEZ

Published: 22 April 2022

http://www.doi.org/10.37201/req/s01.05.2022

Ceftobiprole medocaril is a broad-spectrum 5th-generation cephalosporin with activity against Gram-positives such as methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, and against Gram-negatives such as Pseudomonas aeruginosa. The recommended dose is 500 mg every 8 h in 2-hour infusions. Various clinical trials have demonstrated its usefulness in the treatment of community-acquired pneumonia and nosocomial pneumonia, with the exception of ventilator-associated pneumonia. In summary, it is a very useful antibiotic for the treatment of pneumonia.

Rev Esp Quimioter 2022; 35(Suppl. 1):25-27 [Full-text PDF]